Furthermore, a recent study reported that cenicriviroc (CVC), a dual CCR2 and CCR5 antagonist, was used in a phase IIb clinical trial involving 289 adult patients with nonalcoholic steatohepatitis (NASH) and fibrosis. Here, CCR5 is linked to metabolic dysfunction-associated steatohepatitis.